Implantation of XEN After Failed Trabeculectomy: an Efficient Therapy?

Abstract

Background Trabeculectomy (TE) has been the standard procedure in glaucoma surgery for a long time. This study examined the efficacy and safety profile of XEN45 Gel Stent (XEN) after failed and/or scarred trabeculectomy.

Material and Methods We analysed all files of patients, who received a XEN after insufficient TE and examined changes in intraocular pressure (IOP), IOP-lowering medication, best corrected visual acuity, visual field tests as well as the intra- and postoperative complications recorded within a 12-month follow-up period.

Results 31 eyes of 28 patients were analysed in our study (mean age: 66,2 ± 13,4 years; 39% female; 48% right eye; mean follow-up after TE: 70,3 ± 64,9 months). The mean IOP decreased from 23,5 ± 6,5 to 18,0 ± 5,3 mmHg (− 23,5% compared to baseline-IOP; p = 0,01) while the mean IOP-lowering medication could be reduced from 2,8 ± 1,1 to 1,1 ± 1,5 (p < 0,01) 12 months after XEN-implantation. The mean visual acuity did not change significantly (pre-op: 0,5 ± 0,6 logMAR; 12 months post-op: 0,5 ± 0,6 logMAR). The most common complications postoperatively were choroideal detachment due to postoperative hypotony in 4 eyes (13%), a needling procedure in 9 eyes (29%), a Re-XEN-Implantation in 4 eyes (13%), an open revision of the conjunctiva in 3 eyes (10%), and a Re-TE in 1 eye (3%) as well as an Ahmed-Valve implantation in 2 eyes (6%). Overall, neither needling procedure nor further glaucoma surgery was necessary in 19 eyes (61%). In 10 of 22 evaluable eyes (45%) an IOP reduction of > 20% was achieved 12 months after XEN implantation.

Conclusion XEN could be an effective method to reduce IOP after failed TE. The rate of complications seems to be low and the rate of needling procedures and/or revisions is acceptable.

Key words

XEN - MIGS - failed trabeculectomy - refractory glaucoma

Publication History

Received: 15 March 2021

Accepted: 14 July 2021

Article published online:
27 September 2021

• References/Literatur

• 1 Flaxman SR, Bourne RRA, Resnikoff S. et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. Lancet Glob Health 2017; 12: e1221-e1234
• 2 Tham YC, Li X, Wong TY. et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 2014; 121: 2081-2090
• 3 Schuster AK, Erb C, Hoffmann EM. et al. The Diagnosis and Treatment of Glaucoma. Dtsch Arztebl Int 2020; 13: 225-234
• 4 Schmidl D, Schmetterer L, Garhofer G. et al. Pharmacotherapy of glaucoma. J Ocul Pharmacol Ther 2015; 31: 63-77
• 5 Heijl A, Leske MC, Bengtsson B. et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 10: 1268-1279
• 6 Gedde SJ, Schiffman JC, Feuer WJ. et al. Treatment outcomes in the Tube Versus Trabeculectomy (TVT) study after five years of follow-up. Am J Ophthalmol 2012; 5: 789-803
• 7 Razeghinejad MR, Spaeth GL. A history of the surgical management of glaucoma. Optom Vis Sci 2011; 88: E39-47
• 8 Lavia C, Dallorto L, Maule M. et al. Minimally-invasive glaucoma surgeries (MIGS) for open angle glaucoma: A systematic review and meta-analysis. PLoS One 2017; 12: e0183142
• 9 Sheybani A, Lenzhofer M, Hohensinn M. et al. Phacoemulsification combined with a new ab interno gel stent to treat open-angle glaucoma: Pilot study. J Cataract Refract Surg 2015; 9: 1905-1909
• 10 Reitsamer H, Sng C, Vera V. et al. Two-year results of a multicenter study of the ab interno gelatin implant in medically uncontrolled primary open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol 2019; 257: 983-996
• 11 Schargus M, Theilig T, Rehak M. et al. Outcome of a single XEN microstent implant for glaucoma patients with different types of glaucoma. BMC Ophthalmol 2020; 1: 490
• 12 Gedde SJ, Schiffman JC, Feuer WJ. et al. Three-year follow-up of the tube versus trabeculectomy study. Am J Ophthalmol 2009; 5: 670-684
• 13 Inoue T, Inatani M, Takihara Y, Awai-Kasaoka N. et al. Prognostic risk factors for failure of trabeculectomy with mitomycin C after vitrectomy. Jpn J Ophthalmol 2012; 5: 464-469
• 14 Leske MC, Heijl A, Hussein M. et al. Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003; 1: 48-56
• 15 Edmunds B, Thompson JR, Salmon JF. et al. The National Survey of Trabeculectomy. II. Variations in operative technique and outcome. Eye (Lond) 2001; 4: 441-448
• 16 Edmunds B, Thompson JR, Salmon JF. et al. The National Survey of Trabeculectomy. III. Early and late complications. Eye (Lond) 2002; 3: 297-303
• 17 Kirwan JF, Lockwood AJ, Shah P. et al. Trabeculectomy Outcomes Group Audit Study Group. Trabeculectomy in the 21st century: a multicenter analysis. Ophthalmology 2013; 12: 2532-2539
• 18 Buffault J, Graber M, Bensmail D. et al. Efficacy and safety at 6 months of the XEN implant for the management of open angle glaucoma. Sci Rep 2020; 1: 4527
• 19 Gabbay IE, Allen F, Morley C. et al. Efficacy and safety data for the XEN45 implant at 2 years: a retrospective analysis. Br J Ophthalmol 2020; 8: 1125-1130
• 20 Heidinger A, Schwab C, Lindner E. et al. A Retrospective Study of 199 Xen45 Stent Implantations From 2014 to 2016. J Glaucoma 2019; 1: 75-79
• 21 Hengerer FH, Auffarth G, Conrad-Hengerer I. Comparison of Minimally Invasive XEN45 Gel Stent Implantation in Glaucoma Patients Without and With Prior Interventional Therapies. Ophthalmol Ther 2019; 3: 447-459
• 22 Karimi A, Lindfield D, Turnbull A. et al. A multi-centre interventional case series of 259 ab-interno Xen gel implants for glaucoma, with and without combined cataract surgery. Eye (Lond) 2019; 3: 469-477
• 23 Grover DS, Flynn WJ, Bashford KP. et al. Performance and Safety of a New Ab Interno Gelatin Stent in Refractory Glaucoma at 12 Months. Am J Ophthalmol 2017; 183: 25-36
• 24 Karimi A, Hopes M, Martin KR. et al. Efficacy and Safety of the Ab-interno Xen Gel Stent After Failed Trabeculectomy. J Glaucoma 2018; 10: 864-868
• 25 Sandhu S, Dorey MW. Case Report: Xen Ab Interno Gel Stent Use in a Refractory Glaucoma Patient With Previous Filtration Surgeries. J Glaucoma 2018; 3: e59-e60
• 26 Mansouri K, Bravetti GE, Gillmann K. et al. Two-Year Outcomes of XEN Gel Stent Surgery in Patients with Open-Angle Glaucoma. Ophthalmol Glaucoma 2019; 5: 309-318
• 27 Midha N, Rao HL, Mermoud A. et al. Identifying the predictors of needling after XEN gel implant. Eye (Lond) 2019; 3: 353-357
• 28 Theilig T, Rehak M, Busch C. et al. Comparing the efficacy of trabeculectomy and XEN gel microstent implantation for the treatment of primary open-angle glaucoma: a retrospective monocentric comparative cohort study. Sci Rep 2020; 1: 19337
• 29 Wagner FM, Schuster AK, Emmerich J. et al. Efficacy and safety of XEN^®-Implantation vs. trabeculectomy: Data of a “real-world” setting. PLoS One 2020; 4: e0231614
• 30 Broadway DC, Chang LP. Trabeculectomy, risk factors for failure and the preoperative state of the conjunctiva. J Glaucoma 2001; 3: 237-249